Developer of RNA (ribonucleic acid) interference therapeutics, Tekmira Pharmaceuticals has showcased its lipid nanoparticle (LNP) technology advancements at a scientific conference that took place in Montreal, Quebec.
The symposium, titled Multidisciplinary Approaches to Modern Therapeutics: Joining Forces for a Healthier Tomorrow was co-hosted by the NHPRS (National Health Products Research Society of Canada), CSPT (Canadian Society of Pharmacology & Therapeutics), CSPS (Canadian Society for Pharmaceutical Sciences), and the CC-CRS (Controlled Release Society – Canadian Chapter (CC-CRS), Canadian Society for Pharmaceutical Sciences (CSPS), Canadian Society).
The session undertaken by Tekmira was titled Lipid Nanoparticles for siRNA Delivery and included nebulization, antibody coupling, and latest formulations. The company’s LNP formulations make use of novel indices, which attain good therapeutic indices. Tekmira has also collaborated with Genetech to demonstrate data that integrated antibody fragments and antibodies to LNPs. Coupling LNP formulations to antibody fragments allows active targeting to particular cells and tissues.
Tekmira has also collaborated with a pharmaceutical firm to develop LNP chemistries, which allow LNP particle nebulization. Nebulization is a process of converting liquid medicines to a fine mist, which is used for treating respiratory diseases. The company also announced that it has increased LNP manufacturing for commercialization and late-stage clinical development.
Tekmira’s Chief Executive Officer, Dr. Mark J. Murray stated that the company’s scientists are working towards presenting clinical data from various LNP-enabled products.
Source: http://www.tekmirapharm.com/